Escape mutations in IDH enzymes/second site mutations (Figure 2A): Escape mutations that are likely to restore the pathologic metabolic capabilities of IDH enzymes have been described for both IDH1- and IDH2-mutated AML treated with ivosidenib and enasidenib, respectively. This evidence concerns the gene IDH1 and acute myeloid leukemia.